Cover Image
Market Research Report
Product code 
1070553

Implantable Defibrillators Market by Product Type : Global Opportunity Analysis and Industry Forecast, 2020-2030

Published: | Allied Market Research | 172 Pages | Delivery time: 2-3 business days

Price

Back to Top
Implantable Defibrillators Market by Product Type : Global Opportunity Analysis and Industry Forecast, 2020-2030
Published: March 8, 2022
Allied Market Research
Content info: 172 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global implantable defibrillators market was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030.

Implantable cardioverter defibrillators (ICDs) are devices used to treat patients with heart arrhythmias that occur in the heart's lower chambers or ventricles, which can be life threatening.

ICDs are typically implanted in patients who have a weakened heart, owing to a history of heart blockages and/or heart attacks or in those with heart muscle tissue that are enlarged or thickened. Occasionally, ICDs are implanted in patients who have an inherited heart defect that makes their heart beat abnormally.

Implantable cardioverter defibrillator (ICD) is an equipment or device implanted inside the human body to perform cardioversion, correct pacing, and defibrillation of the heart. The product is generally used in treating sudden cardiac arrest owing to ventricular fibrillation, cardiac arrhythmias, and pulseless ventricular tachycardia.

Implantable defibrillators are battery-powered small devices placed underneath the chest or abdomen to keep track of a patient's heart rate. Increase in palpitation is diagnosed by the device and the normal heart rhythm is restored. These devices play a vital role in preventing sudden cardiac arrest in patients who suffer from sustained ventricular tachycardia or atrial fibrillation. Therefore, ICDs constantly monitor the heart rhythm through electrodes and deliver treatments when an abnormal heart rhythm is detected. The treatments through ICDs include pacing, cardioversion, and defibrillation to restore a normal heart rhythm.

The growth of the implantable defibrillators market is attributed to advancements in technology such as introduction of quadripolar lead devices to improve device programming, extend battery life, and development of magnetic resonance imaging (MRI)-safe ICDs. In addition, a rise in the incidence of atrial fibrillation and the high risk of a sudden cardiac arrest (SCA) fuel the demand for implantable defibrillator devices. Furthermore, introduction of subcutaneous ICD technology in 2012 has revolutionized the treatment technology for cardiac rhythm management through these devices. Boston Scientific's S-ICDs were granted the market clearance in 2012, which was the first commercially available S-ICDs system worldwide. S-ICDs are widely adopted, as they are implanted below the skin without the leads to be placed inside the heart. This fueled the demand for S-ICDs globally, thus driving the growth of the market. However, the presence of alternative treatment and limited insurance coverage are projected to hamper the market growth.

The implantable defibrillator market is segmented based on product type and geography. On the basis of product type, the market is segmented into transvenous implantable cardioverter-defibrillator (T-ICDs), subcutaneous implantable cardioverter defibrillators (S-ICDS), and cardiac resynchronization therapy defibrillator (CRT-D). Geographically, the market has been analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Argentina, Egypt, Israel, South Africa, and rest of LAMEA

The major players operating in the global Implantable Defibrillators market are Abbott, Biotronik SE & Co. KG, Boston Scientific Corporation, Fukuda Denshi Co. Ltd., Imricor Medical Systems, Koninklijke Philips N.V., LivaNova Plc Company, Medtronic Plc, Microport scientific corporation, and Nihon Kohden Corporation. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides in-depth analysis of the global Implantable Defibrillators market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Implantable Defibrillators market growth.

KEY MARKET SEGMENTS

  • By Product Type
    • Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
    • Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
    • Cardiac Resynchronization Therapy Defibrillator (CRT-D)
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA
  • List of key players profiled in the report:
  • Abbott
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Fukuda Denshi Co. Ltd.
  • Imricor Medical Systems
  • Koninklijke Philips N.V.
  • Livanova Plc Company
  • Medtronic Plc
  • Microport Scientific Corporation
  • Nohen Kohden Corporation
Product Code: LI_172091 / A01761

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1.Report Description
  • 1.2.Key Market Segments
  • 1.3.Key Benefits
  • 1.4.Research Methodology
    • 1.4.1.Primary Research
    • 1.4.2.Secondary Research
    • 1.4.3.Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1.CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1.Market Definition and Scope
  • 3.2.Key Findings
    • 3.2.1.Top Investment Pockets
    • 3.2.2.Top Winning Strategies
  • 3.3.Porter's Five Forces Analysis
    • 3.3.1.Bargaining Power of Suppliers
    • 3.3.2.Threat of New Entrants
    • 3.3.3.Threat of Substitutes
    • 3.3.4.Competitive Rivalry
    • 3.3.5.Bargaining Power among Buyers
  • 3.4.Market Share Analysis/Top Player Positioning
    • 3.4.1.Market Share Analysis/Top Player Positioning 2020
  • 3.5.Market Dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6. COVID-19 Impact Analysis

CHAPTER 4: IMPLANTABLE DEFIBRILLATORS MARKET, BY PRODUCT TYPE

  • 4.1.Market Overview
  • 4.1.1Market Size and Forecast, By Product Type
  • 4.2.Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
    • 4.2.1.Key Market Trends, Growth Factors and Opportunities
    • 4.2.2.Market Size and Forecast, By Region
    • 4.2.3.Market Share Analysis, By Country
  • 4.3.Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
    • 4.3.1.Key Market Trends, Growth Factors and Opportunities
    • 4.3.2.Market Size and Forecast, By Region
    • 4.3.3.Market Share Analysis, By Country
  • 4.4.Cardiac Resynchronization Therapy Defibrillator (CRT-D)
    • 4.4.1.Key Market Trends, Growth Factors and Opportunities
    • 4.4.2.Market Size and Forecast, By Region
    • 4.4.3.Market Share Analysis, By Country

CHAPTER 5: IMPLANTABLE DEFIBRILLATORS MARKET, BY REGION

  • 5.1.Market Overview
  • 5.1.1Market Size and Forecast, By Region
  • 5.2.North America
    • 5.2.1.Key Market Trends and Opportunities
    • 5.2.2.Market Size and Forecast, By Product Type
    • 5.2.3.Market Size and Forecast, By Country
    • 5.2.4.United States Implantable Defibrillators Market
      • 5.2.4.1.Market Size and Forecast, By Product Type
    • 5.2.5.Canada Implantable Defibrillators Market
      • 5.2.5.1.Market Size and Forecast, By Product Type
    • 5.2.6.Mexico Implantable Defibrillators Market
      • 5.2.6.1.Market Size and Forecast, By Product Type
  • 5.3.Europe
    • 5.3.1.Key Market Trends and Opportunities
    • 5.3.2.Market Size and Forecast, By Product Type
    • 5.3.3.Market Size and Forecast, By Country
    • 5.3.4.France Implantable Defibrillators Market
      • 5.3.4.1.Market Size and Forecast, By Product Type
    • 5.3.5.Germany Implantable Defibrillators Market
      • 5.3.5.1.Market Size and Forecast, By Product Type
    • 5.3.6.Italy Implantable Defibrillators Market
      • 5.3.6.1.Market Size and Forecast, By Product Type
    • 5.3.7.Spain Implantable Defibrillators Market
      • 5.3.7.1.Market Size and Forecast, By Product Type
    • 5.3.8.U.K Implantable Defibrillators Market
      • 5.3.8.1.Market Size and Forecast, By Product Type
    • 5.3.9.Rest Of Europe Implantable Defibrillators Market
      • 5.3.9.1.Market Size and Forecast, By Product Type
  • 5.4.Asia-Pacific
    • 5.4.1.Key Market Trends and Opportunities
    • 5.4.2.Market Size and Forecast, By Product Type
    • 5.4.3.Market Size and Forecast, By Country
    • 5.4.4.China Implantable Defibrillators Market
      • 5.4.4.1.Market Size and Forecast, By Product Type
    • 5.4.5.Japan Implantable Defibrillators Market
      • 5.4.5.1.Market Size and Forecast, By Product Type
    • 5.4.6.India Implantable Defibrillators Market
      • 5.4.6.1.Market Size and Forecast, By Product Type
    • 5.4.7.South Korea Implantable Defibrillators Market
      • 5.4.7.1.Market Size and Forecast, By Product Type
    • 5.4.8.Australia Implantable Defibrillators Market
      • 5.4.8.1.Market Size and Forecast, By Product Type
    • 5.4.9.Rest of Asia Pacific Implantable Defibrillators Market
      • 5.4.9.1.Market Size and Forecast, By Product Type
  • 5.5.LAMEA
    • 5.5.1.Key Market Trends and Opportunities
    • 5.5.2.Market Size and Forecast, By Product Type
    • 5.5.3.Market Size and Forecast, By Country
    • 5.5.4.Brazil Implantable Defibrillators Market
      • 5.5.4.1.Market Size and Forecast, By Product Type
    • 5.5.5.South Africa, Implantable Defibrillators Market
      • 5.5.5.1.Market Size and Forecast, By Product Type
    • 5.5.6.Saudi Arabia Implantable Defibrillators Market
      • 5.5.6.1.Market Size and Forecast, By Product Type
    • 5.5.7.Rest of LAMEA Implantable Defibrillators Market
      • 5.5.7.1.Market Size and Forecast, By Product Type

CHAPTER 6: COMPANY PROFILES

  • 6.1.Abbott Laboratories
    • 6.1.1.Company Overview
    • 6.1.2.Key Executives
    • 6.1.3.Company snapshot
    • 6.1.4.Operating business segments
    • 6.1.5.Product portfolio
    • 6.1.6.Business Performance
    • 6.1.7.Key Strategic Moves and Developments
  • 6.2.Biotronik Schweiz Ag
    • 6.2.1.Company Overview
    • 6.2.2.Key Executives
    • 6.2.3.Company snapshot
    • 6.2.4.Operating business segments
    • 6.2.5.Product portfolio
    • 6.2.6.Business Performance
    • 6.2.7.Key Strategic Moves and Developments
  • 6.3.Boston Scientific Corporation
    • 6.3.1.Company Overview
    • 6.3.2.Key Executives
    • 6.3.3.Company snapshot
    • 6.3.4.Operating business segments
    • 6.3.5.Product portfolio
    • 6.3.6.Business Performance
    • 6.3.7.Key Strategic Moves and Developments
  • 6.4.FUKUDA DENSHI CO. Ltd
    • 6.4.1.Company Overview
    • 6.4.2.Key Executives
    • 6.4.3.Company snapshot
    • 6.4.4.Operating business segments
    • 6.4.5.Product portfolio
    • 6.4.6.Business Performance
    • 6.4.7.Key Strategic Moves and Developments
  • 6.5.IMRICOR MEDICAL SYSTEMS
    • 6.5.1.Company Overview
    • 6.5.2.Key Executives
    • 6.5.3.Company snapshot
    • 6.5.4.Operating business segments
    • 6.5.5.Product portfolio
    • 6.5.6.Business Performance
    • 6.5.7.Key Strategic Moves and Developments
  • 6.6.Koninklijke Philips N.V.
    • 6.6.1.Company Overview
    • 6.6.2.Key Executives
    • 6.6.3.Company snapshot
    • 6.6.4.Operating business segments
    • 6.6.5.Product portfolio
    • 6.6.6.Business Performance
    • 6.6.7.Key Strategic Moves and Developments
  • 6.7.LivaNova PLC
    • 6.7.1.Company Overview
    • 6.7.2.Key Executives
    • 6.7.3.Company snapshot
    • 6.7.4.Operating business segments
    • 6.7.5.Product portfolio
    • 6.7.6.Business Performance
    • 6.7.7.Key Strategic Moves and Developments
  • 6.8.Medtronic Plc.
    • 6.8.1.Company Overview
    • 6.8.2.Key Executives
    • 6.8.3.Company snapshot
    • 6.8.4.Operating business segments
    • 6.8.5.Product portfolio
    • 6.8.6.Business Performance
    • 6.8.7.Key Strategic Moves and Developments
  • 6.9.Microport Scientific Corp
    • 6.9.1.Company Overview
    • 6.9.2.Key Executives
    • 6.9.3.Company snapshot
    • 6.9.4.Operating business segments
    • 6.9.5.Product portfolio
    • 6.9.6.Business Performance
    • 6.9.7.Key Strategic Moves and Developments
  • 6.10.Nohen Kohden Corporation
    • 6.10.1.Company Overview
    • 6.10.2.Key Executives
    • 6.10.3.Company snapshot
    • 6.10.4.Operating business segments
    • 6.10.5.Product portfolio
    • 6.10.6.Business Performance
    • 6.10.7.Key Strategic Moves and Developments

LIST OF TABLES

  • TABLE 1.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 2.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET FOR TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (T-ICDS), BY REGION, 2020-2030 ($MILLION)
  • TABLE 3.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET FOR SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (S-ICDS), BY REGION, 2020-2030 ($MILLION)
  • TABLE 4.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D), BY REGION, 2020-2030 ($MILLION)
  • TABLE 5.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 6.NORTH AMERICA IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
  • TABLE 7.NORTH AMERICA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 8.UNITED STATES IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 9.CANADA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 10.MEXICO IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 11.EUROPE IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
  • TABLE 12.EUROPE IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 13.FRANCE IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 14.GERMANY IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 15.ITALY IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 16.SPAIN IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 17.UNITED KINGDOM IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 18.REST OF EUROPE IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 19.ASIA-PACIFIC IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
  • TABLE 20.ASIA-PACIFIC IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 21.CHINA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 22.JAPAN IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 23.INDIA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 24.SOUTH KOREA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 25.AUSTRALIA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 26.REST OF ASIA PACIFIC IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 27.LAMEA IMPLANTABLE DEFIBRILLATORS, BY Region, 2020-2030 ($MILLION)
  • TABLE 28.LAMEA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 29.BRAZIL IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 30.SOUTH AFRICA, IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 31.SAUDI ARABIA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 32.REST OF LAMEA IMPLANTABLE DEFIBRILLATORS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 33.ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 34.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 35.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 36.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 37.ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 38.BIOTRONIK SCHWEIZ AG: KEY EXECUTIVES
  • TABLE 39.BIOTRONIK SCHWEIZ AG: COMPANY SNAPSHOT
  • TABLE 40.BIOTRONIK SCHWEIZ AG: OPERATING SEGMENTS
  • TABLE 41.BIOTRONIK SCHWEIZ AG: PRODUCT PORTFOLIO
  • TABLE 42.BIOTRONIK SCHWEIZ AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 43.BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 44.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 45.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 46.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 47.BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 48.FUKUDA DENSHI CO.,LTD: KEY EXECUTIVES
  • TABLE 49.FUKUDA DENSHI CO.,LTD: COMPANY SNAPSHOT
  • TABLE 50.FUKUDA DENSHI CO.,LTD: OPERATING SEGMENTS
  • TABLE 51.FUKUDA DENSHI CO.,LTD: PRODUCT PORTFOLIO
  • TABLE 52.FUKUDA DENSHI CO.,LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 53.IMRICOR MEDICAL SYSTEMS: KEY EXECUTIVES
  • TABLE 54.IMRICOR MEDICAL SYSTEMS: COMPANY SNAPSHOT
  • TABLE 55.IMRICOR MEDICAL SYSTEMS: OPERATING SEGMENTS
  • TABLE 56.IMRICOR MEDICAL SYSTEMS: PRODUCT PORTFOLIO
  • TABLE 57.IMRICOR MEDICAL SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 58.KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 59.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 60.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 61.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 62.KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 63.LIVANOVA PLC: KEY EXECUTIVES
  • TABLE 64.LIVANOVA PLC: COMPANY SNAPSHOT
  • TABLE 65.LIVANOVA PLC: OPERATING SEGMENTS
  • TABLE 66.LIVANOVA PLC: PRODUCT PORTFOLIO
  • TABLE 67.LIVANOVA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 68.MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 69.MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 70.MEDTRONIC PLC: OPERATING SEGMENTS
  • TABLE 71.MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 72.MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 73.MICROPORT SCIENTIFIC CORP: KEY EXECUTIVES
  • TABLE 74.MICROPORT SCIENTIFIC CORP: COMPANY SNAPSHOT
  • TABLE 75.MICROPORT SCIENTIFIC CORP: OPERATING SEGMENTS
  • TABLE 76.MICROPORT SCIENTIFIC CORP: PRODUCT PORTFOLIO
  • TABLE 77.MICROPORT SCIENTIFIC CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78.NOHEN KOHDEN CORPORATION: KEY EXECUTIVES
  • TABLE 79.NOHEN KOHDEN CORPORATION: COMPANY SNAPSHOT
  • TABLE 80.NOHEN KOHDEN CORPORATION: OPERATING SEGMENTS
  • TABLE 81.NOHEN KOHDEN CORPORATION: PRODUCT PORTFOLIO
  • TABLE 82.NOHEN KOHDEN CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET SEGMENTATION
  • FIGURE 2.GLOBAL IMPLANTABLE DEFIBRILLATORS MARKET
  • FIGURE 3.SEGMENTATION IMPLANTABLE DEFIBRILLATORS MARKET
  • FIGURE 4.TOP INVESTMENT POCKET IN IMPLANTABLE DEFIBRILLATORS MARKET
  • FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
  • FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
  • FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
  • FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 11.LOW THREAT OF SUBSTITUTION
  • FIGURE 12.HIGH COMPETITIVE RIVALRY
  • FIGURE 13.TOP PLAYER POSITIONING, 2020
  • FIGURE 14.MARKET SHARE ANALYSIS, 2020
  • FIGURE 15.RESTRAINTS AND DRIVERS: IMPLANTABLE DEFIBRILLATORS MARKET
  • FIGURE 16.IMPLANTABLE DEFIBRILLATORS MARKET SEGMENTATION, BY PRODUCT TYPE
  • FIGURE 17.IMPLANTABLE DEFIBRILLATORS MARKET FOR TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (T-ICDS), BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 18.IMPLANTABLE DEFIBRILLATORS MARKET FOR SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (S-ICDS), BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 19.IMPLANTABLE DEFIBRILLATORS MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D), BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 20.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 21.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 22.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 23.BIOTRONIK SCHWEIZ AG: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 24.BIOTRONIK SCHWEIZ AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 25.BIOTRONIK SCHWEIZ AG: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 26.BOSTON SCIENTIFIC CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 28.BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 29.FUKUDA DENSHI CO.,LTD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.FUKUDA DENSHI CO., LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 31.FUKUDA DENSHI CO., LTD: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 32.IMRICOR MEDICAL SYSTEMS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 33.IMRICOR MEDICAL SYSTEMS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 34.IMRICOR MEDICAL SYSTEMS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 35.KONINKLIJKE PHILIPS N.V.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 37.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 38.LIVANOVA PLC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.LIVANOVA PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 40.LIVANOVA PLC: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 41.MEDTRONIC PLC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 42.MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 43.MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 44.MICROPORT SCIENTIFIC CORP: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.MICROPORT SCIENTIFIC CORP: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 46.MICROPORT SCIENTIFIC CORP: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 47.NOHEN KOHDEN CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 48.NOHEN KOHDEN CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 49.NOHEN KOHDEN CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)